Ultimately, we want our biomarker development work to enable faster and more accurate MS diagnosis and to improve disease progression assessment. These articles (here and here) in Multiple Sclerosis and…

MS is an autoimmune disease, the most common neurological disease of young adults. It damages neurons in the brain and spinal cord (the central nervous system).

MS affects 400,000 individuals in the U.S and 2.5 million worldwide.

Although substantial advances have been made in the development of therapeutic treatments, the drugs currently available to MS patients do not significantly alter the long-term prognosis of the disease. Better markers that represent the biological activity of the disease process and the response to therapy are desperately needed, as are novel therapies that halt disease progression rather than just modify it.